BetterLife Pharma CEO Ahmad Doroudian joined Steve Darling to share details the company has obtained the first set of neurological receptor binding data on its lead compound, 2-bromo- LSD which was generated by Eurofins Discovery.
Doroudian saying the TD-0148A which is a second-generation Lysergic Acid Diethylamide or LSD derivative molecule, and the company feels will mimic the projected therapeutic potential of LSD without causing the undesirable psychoactive dissociative side effects, such as hallucinations. Doroudian sad this initial data shows significant TD-0148A binding to receptors while there is none to limited binding to receptors such as 5-HT3, GABA-A1, and NMDA receptors.